SAN DIEGO, March 29, 2026 (GLOBE NEWSWIRE) — The regulation agency of Robbins Geller Rudman & Dowd LLP publicizes purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) frequent inventory between August 3, 2023 and December 26, 2025, each dates inclusive (the “Class Period”), have till Monday, April 6, 2026 to hunt appointment as lead plaintiff of the Ultragenyx class motion lawsuit. Captioned Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), the Ultragenyx class motion lawsuit fees Ultragenyx in addition to sure of Ultragenyx’ executives with violations of the Securities Alternate Act of 1934.
For those who suffered substantial losses and want to function lead plaintiff of the Ultragenyx class motion lawsuit, please present your info right here:
https://www.rgrdlaw.com/cases-ultragenyx-pharmaceutical-inc-class-action-lawsuit-rare.html
CASE ALLEGATIONS: Ultragenyx is a biopharmaceutical firm that focuses on the identification, acquisition, growth, and commercialization of novel merchandise for the therapy of uncommon and ultra-rare genetic ailments.
The Ultragenyx class motion lawsuit alleges that defendants all through the Class Interval made false and/or deceptive statements and/or didn’t disclose that: (i) defendants created the misunderstanding that they possessed dependable info pertaining to the results of setrusumab on sufferers with variable kinds of Osteogenesis Imperfecta (“OI”), whereas additionally minimizing threat that sufferers in Ultragenyx’ Part III Orbit examine would fail to realize a statistically important discount in annualized fracture price (“AFR”), such that the second interim evaluation may very well be carried out and introduced to the investing public; and (ii) in fact, Ultragenyx’ optimism within the Part III Orbit examine’s outcomes and interim evaluation benchmark had been misplaced as a result of Ultragenyx didn’t convey the danger related to basing such threshold figures on Part II outcomes that had no placebo management group for applicable comparability and thus had not dominated out that the discount in AFR from that examine might merely be triggered by an elevated customary of care and the placebo impact of being supplied a novel therapy.
More Read
THE LEAD PLAINTIFF PROCESS: The Personal Securities Litigation Reform Act of 1995 permits any investor who bought or acquired Ultragenyx frequent inventory through the Class Interval to hunt appointment as lead plaintiff within the Ultragenyx class motion lawsuit. A lead plaintiff is usually the movant with the best monetary curiosity within the reduction sought by the putative class who can be typical and sufficient of the putative class. A lead plaintiff acts on behalf of all different class members in directing the Ultragenyx investor class motion lawsuit. The lead plaintiff can choose a regulation agency of its option to litigate the Ultragenyx shareholder class motion lawsuit. An investor’s capability to share in any potential future restoration will not be dependent upon serving as lead plaintiff of the Ultragenyx class motion lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is likely one of the world’s main complicated class motion corporations representing plaintiffs in securities fraud and shareholder rights litigation. Our Agency ranked #1 on the newest ISS Securities Class Motion Companies High 50 Report, recovering greater than $916 million for traders in 2025. This marks our fourth #1 rating prior to now 5 years. And in these 5 years alone, Robbins Geller recovered $8.4 billion for traders – $3.4 billion greater than another regulation agency. With 200 legal professionals in 10 workplaces, Robbins Geller is likely one of the largest plaintiffs’ corporations on the earth, and the Agency’s attorneys have obtained lots of the largest securities class motion recoveries in historical past, together with the most important ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please go to the next web page for extra info:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
More Read
Previous outcomes don’t assure future outcomes. Companies could also be carried out by attorneys in any of our workplaces.
